12 April 2019

APLAR interviews: RA treatment in 2030

APLAR Clinical Conditions Rheumatoid Arthritis

Over the next decade, we will get smarter about how we treat rheumatoid arthritis, says Iain McInnes, a professor of experimental medicine at the University of Glasgow.

“We’ve got a whole range of medicines,” he says. “[But] we haven’t become terribly smart at using them wisely.”

By 2030, rheumatologists will be using precision medicine and biomarkers to predict which drugs will work for which patients instead of relying on a trial-and-error approach.

“And in that respect, we’ll be following the cancer field,” he says.

Rheumatology Republic reporter Felicity Nelson caught up with Professor McInnes (pictured above) at APLAR-ARA 2019 in Brisbane this week.